FDA Brief

FDA warning letters

A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.

10 letters match. Newest first.

  1. Peak Performance Peptides

    Peak Performance Peptides sold unapproved injectable peptide drugs, including semaglutide and retatrutide, without FDA approval.

    High risk
  2. Royal Peptides LLC

    FDA warned Royal Peptides LLC that seven peptide products sold on its website are unapproved new drugs.

    High risk
  3. NuScience Peptides LLC

    FDA warned NuScience Peptides that it sells unapproved injectable peptide drugs, including GLP-1 and tesamorelin products, on its website.

    High risk
  4. Peptide Partners LLC

    Peptide Partners LLC sold seven unapproved injectable peptide drugs online with disease-treatment claims, FDA says.

    High risk
  5. TXP Innovations LLC dba Tex Peptides

    FDA warned Dallas peptide seller TXP Innovations (Tex Peptides) that its website sells unapproved injectable drugs, including semaglutide and tirzepatide.

    High risk
  6. Ket Plug / ketaminelab.org and buyketaminepowderonline.com

    FDA warns Ket Plug that its ketamine websites sell unapproved, misbranded ketamine powder to U.S. consumers.

    High risk
  7. Wholesale Peptide

    FDA warns Wholesale Peptide that its website sells Prostamax and Gonadorelin as unapproved new drugs.

    High risk
  8. Gram Peptides

    Gram Peptides sold unapproved injectable peptide drugs and bacteriostatic water online as new drugs, FDA says.

    High risk
  9. PekCura Labs

    FDA warned PekCura Labs that its GLP-1-S, GLP-2-T, GLP-3-R, and bacteriostatic water products are unapproved new drugs sold online.

    High risk
  10. Atomix LLC

    FDA warned Atomix LLC that its website sells unapproved SARM drugs MK-2866 and RAD-140 as new drugs without approval.

    High risk